Dublin, Aug. 04, 2016 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of the "Global Influenza Market - Vaccines and Therapeutics" report to their offering.
Worldwide market for Influenza Vaccines is analyzed in both volumes in doses and value in USD for the period from 2012 through to 2022. The market for influenza therapeutics is analyzed in terms of value only at a global level. The global market for overall influenza is estimated to be US$6.1 billion in 2016 and anticipated to reach US$10.2 billion by 2022, witnessing a robust 8.5% CAGR between 2016 and 2022. Vaccines account for about 80% of the influenza market while therapeutics account for the remaining. However, therapeutics segment is projected to be the fastest growing with a CAGR of 11% during the aforementioned analysis period.
The influenza virus has been implicated in infecting millions of individuals on an annual basis, with vaccination programs against seasonal influenza infections necessitating the manufacture of hundreds of million doses within a very short time period. The emergence of innovative production systems based on mammalian or insect cell cultures have resulted in surmount the hurdles associated with the egg-based production system. These industrially well-established production systems provide a faster and more flexible response to pandemic threats.
The existing range of influenza vaccines are produced in fertilized eggs, the embryo of which is infected in order that the virus can proliferate. Following a period of incubation, the virus is harvested and purified. This system of production is complicated and lacking in the event of a pandemic due to the possibility of generating low yields, not being amenable to rapid scale-up and being dependent on the availability of eggs.
Global authorities have acknowledged problems associated with manufacturing vaccines based on eggs, resulting in creating a need for developing alternative vaccine production systems. The current scenario has been focusing on the development of manufacturing systems based on plants, bacteria, yeast and cell cultures.
The report reviews, analyses and projects the Influenza therapeutics market at the global level while vaccines market is explored in and the regional markets including North America, Europe, Asia-Pacific, South & Central America and Middle East & Africa.
Key Topics Covered:
Part A: Global Market Perspective
1. Introduction
1.1 Product Outline
1.1.1 What is Influenza?
1.1.2 Influenza Virus Types
1.1.3 Influenza Types
1.1.3.1 Seasonal Influenza
1.1.3.2 Pandemic Influenza
1.1.3.3 Zoonotic Influenza
1.1.4 Treatment of Influenza
1.1.4.1 Neuraminidase Inhibitors
1.1.4.2 M2 Inhibitors
1.1.5 Influenza Vaccine Production Technologies
1.1.5.1 Egg Based Vaccine Manufacturing Technology
1.1.5.2 Cell Culture Based Vaccine Manufacturing Technology
1.1.5.3 Recombinant Production Technology
2. Major Products In Pipeline
2.1 Influenza Vaccines in Pipeline
2.2 Influenza Therapeutics in Pipeline
3. Key Market Trends
3.1 Development of Novel Anti-Influenza Drugs to be Guided by Research
3.2 Potential to Reduce Influenza-Associated Atrial Fibrillation Shown by Flu Vaccine
3.3 Designer Drugs for Combating Flu
3.4 Influenza Vaccines Based on Cell Culture Gaining Traction
- Production of Influenza Vaccine Using Mammalian Cell Culture
- Production of Influenza Vaccine Using Insect Cell Culture
3.5 Emerging Technologies for Influenza Vaccine Production
- Virus-Like Particles Influenza Vaccine
- Vectored Influenza Vaccine
- Cell-Based Produced LAIV
3.6 Traditional Seasonal Flu Vaccines Confront Challenge from Plant-Based Vaccines!
3.7 HHS Makes Progress in Developing Innovative Drug for Treating Influenza
4. Key Global Players
- Abbott Laboratories
- Astrazeneca PLC
- Biocryst Pharmaceuticals, Inc.
- CSL Limited
- Daiichi Sankyo Co., Ltd.
- Glaxosmithkline PLC
- Hualan Biological Engineering Inc.
- Instituto Butantan
- Mitsubishi Tanabe Pharma Corporation
- Nanotherapeutics Inc.
- Protein Sciences Corporation
- Roche Holding AG
- Sanofi SA
- Shanghai Institute of Biological Products Co., Ltd.
- Shionogi & Co., Ltd.
- Sinovac Biotech Ltd.
5. Key Business Trends
- Roche in an Alliance with Shionogi for Anti-Flu Drug S-033188
- Unveiling of Janssen Diagnostics' New Idylla Respiratory IFV-RSV Panel
- Establishment of a New Corporate Office for Seqirus in the United Kingdom
- Seqirus' FLUAD (Influenza Vaccine, Adjuvanted) Approved by US FDA
- Mexican Regulatory Authorities Approved Flublok® Influenza Vaccine for Adults 18 and Older
- Seqirus, World's No.2 Influenza Vaccine Provider
- Sanofi Pasteur Presented New Synthetic Vaccine COBRA at the World Vaccine Congress in Spain
- First CLIA-Waived, Real-Time PCR Test for Influenza A and B Detection in 20 Minutes
- Nationwide Availability of Flublok® Influenza Vaccine
- Sinovac Supplies Seasonal Influenza Vaccine for 2015 Vaccination Campaign in Beijing
- Daiichi Sankyo Receives License to Develop and Commercialize FluMist® Quadrivalent in Japan
- Janssen and the Scripps Research Institute to Develop a Universal Flu Vaccine
- Novartis Influenza Vaccine Business Acquired by CSL
- GSK and bioCSL Amp Flu Vaccine Dose Count Shipped to the US
- Sanofi Pasteur's Flu Vaccines Meet the Immunization Needs of People of Multiple Age Groups
- FDA Approved Protein Sciences' Flublok® Influenza Vaccine Formulated for the 2015-16 Flu Season
- Outperformance of Flublok® Quadrivalent Compared to Conventional Influenza Vaccine
- bioCSL Receives Exclusive Global Rights to Commercialize RAPIVAB®
- Flublok® Receives FDA Regulatory Exclusivity for 12 Years under the Affordable Care Act
- Cipla Joined Forces with Serum Institute for Exclusive Sale of Nasovac-S Flu Vaccine in India
- Zydus Cadila to Introduce 10 Shots in the Indian Vaccines Market
- Daiichi Sankyo Partner with Chemo-Sera-Therapeutic Research Institute to Sell Kaketsuken
- US FDA Licensed Protein Sciences' New York Production Plant for Producing Flublok®
- Japan Vaccine Applied for the Production and Sales Approval for The Vaccine in Japan
- Release of Serum Institute's NasoVac S Vaccine to Protect People from H1N1 Virus and Influenza A and B
- Alere i Influenza A & B test, the First-Ever CLIA Waived Molecular Test to Identify and Differentiate Influenza A and B Virus within 15 Minutes
- CDC Receives Letter from Connecticut Representatives Urging the Purchase of Protein Sciences' Flublok Vaccine
- Protein Sciences Form Pact to Assess Possible Sources for Flublok Influenza Vaccine from Japan
- First Ever Approval from FDA for an Intravenous Flu Drug
- Baxter's Patented Vero Cell Technology Platform Purchased by Nanotherapeutics
- Protein Sciences' Flublok® Influenza Vaccine Effective Against H3N2 Viruses
- Sanofi Pasteur Received Approval for the Supplemental Biologics License Application for Fluzone Intradermal Quadrivalent Vaccine from the US FDA
- US FDA Approval for Protein Sciences' Flublok Influenza Vaccine for People Aged 18 and Older
- Liomont Granted with an Exclusive License to Flublok® and Panblok® Influenza Vaccines for the Mexico Market and other Latin American Nations
- Beijing CDC Chosen Sinovac to be a Supplier of Seasonal Influenza Vaccines to the Citizens of Beijing for 2014
- Divestiture of Abbott's Ex-US Branded Generic Drug Business
- Janssen and Vertex Inked an Exclusive License Deal to Develop, Produce and Commercialize VX-787
- BARDA Exercised Option Period 2 of its Deal with Protein Sciences Corporation to Develop Flublok® and Panblok®
- FDA Grants First Time Approval for Producing Cell-Based Flu Vaccines in the US
- Astellas Pharma Submitted Application for Marketing Approval of Recombinant Influenza HA Vaccine in Japan
- Japanese Ministry of Health, Labour and Welfare Chosen Kitasato Daiichi Sankyo Vaccine for the Initiative of Cell Culture Vaccine Production Facility Capacity Building
- Clinical Trial Application with CFDA Submitted by Sinovac for its Patented H7N9 Vaccine
- Acquisition of Key Supplier to BD Diagnostics' Point-of-Care Instrument Platform by BD
- Daiichi Sankyo's Inavir® Inhibitor Approved for Use in the Japanese Market
- AstraZeneca Receives EC Approval for Fluenz Tetra to Treat Seasonal Influenza in People aged 2-18 Years
- US FDA Approved GSK's H5N1 Virus Monovalent Vaccine, Adjuvanted for Adults aged 18 and Older
- New Phase III Clinical Studies of Recombinant Seasonal Influenza HA Vaccine ASP7374 Completed Successfully
- PHARMAC Signed Influenza Vaccine Supply Deals with Abbott and GSK
- US FDA's Proposed New Standards for Test Performance Improvement Accepted by BD
- Fluzone High-Dose Vaccine Evidenced Superior Immune Responses than Standard Dose Fluzone Vaccine in the Prevention of Influenza in Older Adults
- FDA Released the First lots of Sanofi Pasteur's Fluzone® for Shipment for the 2013-2014 Season
- Special 510(k) Clearances Granted for Quidel's Updated Package Inserts for its Rapid Diagnostic Tests for Influenza
- Medicago to Become the Joint Venture Company of Mitsubishi Tanabe Pharma and Philip Morris Investments
- A New Drug Application to the Ministry of Health, Labour and Welfare in Japan for the Cell Culture-Based Pandemic Influenza Vaccine Filed by Kitasato Daiichi Sankyo Vaccine
- FDA Approved Fluzone® Quadrivalent Vaccine for use in Patients of All Age Groups
- New Vaccine for Protection from H7N9 Influenza Virus to be Developed by Protein Sciences
- Production of Influenza Vaccine Restarted by bioCSL for the Australian Market
- GSK's Quadrivalent Influenza Vaccine Receives Approval from PEI in Germany and MHRA in the UK
- Protein Sciences' Flublok® Influenza Vaccine Receives Approval from the US FDA
- FDA Extends its Approval for Tamiflu to Treat Influenza in Infants Aged Two Weeks and Older
- First Intramuscular Vaccine to Cover Against Four Influenza Strains Received FDA Approval
- Protein Sciences Signs Deal with Pfizer to Broaden Vaccine Production Operations
- Daiichi Sankyo Filed an Application for a Partial Label Modification in Japan to Produce and Market Inavir® Dry Powder Inhaler
- Outline of Phase II and Phase III Clinical Studies for Sanofi Pasteur's Investigational QIV Displayed at IDWeek
- US Government Selected CSL Biotherapies for Supplying Pre-Pandemic and Pandemic Vaccine Antigens
- Beijing CDC Chosen Sinovac for Supplying Seasonal Influenza Vaccine to Beijing Citizens
- Restructuring of Infectious Diseases and Vaccines R&D Operations by MedImmune
- GSK Filed Regulatory Applications for Two of its Influenza Vaccines
- Baxter's VEPACEL Pre-pandemic Influenza Vaccine Approved by European Commission
- FluMist Quadrivalent, the first quadrivalent influenza vaccine approved by the FDA
- Zydus Cadila, the First Indian Pharma Firm to Release Swine Flu Vaccine
6. Global Market Overview
6.1 Global Influenza Vaccines Market Overview
6.1.1 Global Influenza Vaccines Market Overview by Geographic Region
6.1.1.1 Market Analysis in Doses
6.1.1.2 Market Analysis in USD
6.2 Global Influenza Therapeutics Market Overview
For more information visit http://www.researchandmarkets.com/research/mhwq4m/global_influenza